Unknown

Dataset Information

0

Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.


ABSTRACT: Antibiotic resistance in Pseudomonas aeruginosa biofilms necessitates the need for novel antimicrobial therapy with anti-biofilm properties. Bacteriophages (phages) are recognized as an ideal biopharmaceutical for combating antibiotic-resistant bacteria especially when used in combination with antibiotics. However, previous studies primarily focused on using phages against of P. aeruginosa biofilms of laboratory strains. In the present study, biofilms of six P. aeruginosa isolated from cystic fibrosis and wound patients, and one laboratory strain was treated singly and with combinations of anti-Pseudomonas phage PEV20 and ciprofloxacin. Of these strains, three were highly susceptible to the phage, while one was partially resistant and one was completely resistant. Combination treatment with PEV20 and ciprofloxacin enhanced biofilm eradication compared with single treatment. Phage and ciprofloxacin synergy was found to depend on phage-resistance profile of the target bacteria. Furthermore, phage and ciprofloxacin combination formulation protected the lung epithelial and fibroblast cells from P. aeruginosa and promoted cell growth. The results demonstrated that thorough screening of phage-resistance is crucial for designing phage-antibiotic formulation. The addition of highly effective phage could reduce the ciprofloxacin concentration required to combat P. aeruginosa infections associated with biofilm in cystic fibrosis and wound patients.

SUBMITTER: Chang RYK 

PROVIDER: S-EPMC6768630 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5615211 | BioStudies
2012-01-01 | S-EPMC3302570 | BioStudies
2019-01-01 | S-EPMC6783858 | BioStudies
2018-01-01 | S-EPMC6174101 | BioStudies
2017-01-01 | S-EPMC5492357 | BioStudies
2017-01-01 | S-EPMC5226664 | BioStudies
2020-01-01 | S-EPMC7479825 | BioStudies
2019-01-01 | S-EPMC6521218 | BioStudies
2016-01-01 | S-EPMC4937139 | BioStudies
2021-01-01 | S-EPMC7830274 | BioStudies